0
Original Research: COPD |

Increased Systemic Inflammation Is a Risk Factor for COPD Exacerbations*

Karin H. Groenewegen, MD; Dirkje S. Postma, MD, PhD; Wim C. J. Hop, PhD; Pascal L. M. L. Wielders, MD; Noel J. J. Schlösser, MD; Emiel F. M. Wouters, MD, FCCP; for the COSMIC Study Group
Author and Funding Information

*From the Department of Respiratory Medicine (Drs. Groenewegen and Wouters), University Hospital Maastricht, Maastricht; Department of Respiratory Medicine (Dr. Postma), University Medical Center Groningen, University of Groningen, Groningen; Department of Epidemiology and Biostatistics (Dr. Hop), Erasmus Medical Center Rotterdam, Rotterdam; Department of Respiratory Medicine (Dr. Wielders), Catharina Hospital Eindhoven, Eindhoven; and Department of Respiratory Medicine (Dr. Schlösser), Central Military Hospital Utrecht, Utrecht, the Netherlands.

Correspondence to: Karin H. Groenewegen, MD, Department of Respiratory Medicine, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, the Netherlands; e-mail: ksi@lung.azm.nl


*From the Department of Respiratory Medicine (Drs. Groenewegen and Wouters), University Hospital Maastricht, Maastricht; Department of Respiratory Medicine (Dr. Postma), University Medical Center Groningen, University of Groningen, Groningen; Department of Epidemiology and Biostatistics (Dr. Hop), Erasmus Medical Center Rotterdam, Rotterdam; Department of Respiratory Medicine (Dr. Wielders), Catharina Hospital Eindhoven, Eindhoven; and Department of Respiratory Medicine (Dr. Schlösser), Central Military Hospital Utrecht, Utrecht, the Netherlands.


Chest. 2008;133(2):350-357. doi:10.1378/chest.07-1342
Text Size: A A A
Published online

Background: COPD is characterized by episodic increases in respiratory symptoms, so-called exacerbations. COPD exacerbations are associated with an increase in local and systemic inflammation. Data of a previously published study in a well-characterized COPD cohort were analyzed to define predictive factors of acute exacerbations, particularly focusing on systemic inflammation.

Objective: To determine if an elevated systemic inflammatory status measured at baseline is related to the occurrence of acute exacerbations in patients with COPD.

Methods: The occurrence of moderate (requiring oral prednisolone) and severe exacerbations (requiring hospitalization) was prospectively recorded over 1 year. At the beginning of the study, lung function values (FEV1, FVC, functional residual capacity, and diffusion capacity of the lung for carbon monoxide [Dlco]) and serum levels of C-reactive protein, fibrinogen, lipopolysaccharide binding protein, tumor necrosis factor (TNF)-α, and its soluble receptors (soluble TNF receptors 55 and 75) as markers of systemic inflammation were determined.

Results: Two hundred seventy-seven person-years of follow-up were analyzed in the total group of 314 patients: 186 patients were responsible for 411 exacerbations (374 moderate and 37 severe). Multivariate analyses showed that a higher initial fibrinogen level and a lower FEV1 predicted a higher rate of both moderate and severe exacerbations. Additional independent predictors of a severe exacerbation were a higher number of prestudy severe exacerbations and lower Dlco. A higher number of prestudy moderate exacerbations was the only additional independent risk factor for the rate of moderate exacerbations.

Conclusion: This study demonstrates that besides lung function impairment systemic inflammation manifested by elevated fibrinogen levels is an independent risk factor for exacerbations of COPD. Attenuation of systemic inflammation may offer new perspectives in the management of COPD patients to reduce the burden of exacerbations.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543